FDA
-
-
-
-
-
-
-
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
-
-
-
-
-
-
-
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
-
-
-
-
-
-
-
Aytu BioScience (AYTU) Announces Exclusive Agreement with Lupin Pharma Canada to Commercialize Adzenys XR-ODT and Cotempla XR-ODT
-
-
-
-
-
-
-
Aytu BioScience (AYTU) Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement
-
-
-
-
-
-
-
Aytu BioScience (AYTU) Continues Availability of Adzenys XR-ODT(R)
-
-
-
-
-
-
-
Aytu BioScience (AYTU) Granted Fourth Patent License for AR101/Enzastaurin
-
-
-
-
-
-
-
Aytu BioPharma Announces Pricing of Public Offering
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

